PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1403391
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1403391
According to Stratistics MRC, the Global Metagenomics Market is accounted for $2.0 billion in 2023 and is expected to reach $6.5 billion by 2030 growing at a CAGR of 18.5% during the forecast period. The study of genetic material extracted from environmental samples is known as metagenomics. To investigate genes and microbial pathways, the research is characterized as a tool for the microbial community. It offers a strong lens with the capacity to comprehend the entirety of the living universe. Researchers may now access a wide range of microbial variety and gain a better grasp of the microbial ecology thanks to technology.
According to a report from the National Human Genome Research Institute as of July 2017, approximately 743 terabytes (743,000 gigabytes) of data are generated during the sequencing of a single human genome, compared to 16.2 gigabytes at the beginning of the human genome project in 2001.
Metagenomics has gained traction in clinical settings for disease diagnostics, personalized medicine, and understanding the human microbiome's role in health and disease. It allows for comprehensive analysis of microbial communities, aiding in disease identification, treatment optimization, and drug development. These biomarkers could potentially serve as diagnostic indicators or therapeutic targets for various conditions. These are the factors propelling the growth of the market.
The management of sensitive information raises ethical and privacy concerns that must be addressed, particularly with relation to the use of human microbiome data. Furthermore, regional differences in the laws governing the use of genetic and microbiological data have an effect on commercialization and research initiatives. Furthermore, managing, preserving, and deciphering this data might be difficult and call for specific knowledge, which could further impede the market's expansion.
Growing apprehension about the effects of microbiomes on agriculture, human health, and the environment has resulted in more financing and research projects. The area of metagenomics is developing quickly due to ongoing advances in technology and analytical techniques. The understanding of microbial communities is always growing as a result of new findings and insights. The market for metagenomics research is growing as a result of increased funding from governmental bodies, academic institutions, and commercial businesses.
The high expense of data analysis, computer resources, and sequencing technology is a major hurdle that prevents smaller research organizations or businesses with tighter budgets from using them. Metagenomic investigations create enormous amounts of data, which calls for advanced computing infrastructure and bioinformatics knowledge. One of the challenges in evaluating various microbial communities is their complexity. This is the element impeding the market's expansion.
us that causes COVID-19, SARS-CoV-2, has been identified and detected thanks in large part to metagenomics. Metagenomic sequencing has been utilized by researchers to track mutations, find new strains, and comprehend the virus's dissemination. Because it sheds light on the virus's genetic composition, metagenomics has aided in the creation of vaccines. Scientists have used this knowledge to better understand how the virus could change over time and develop vaccinations, which has improved vaccine effectiveness.
The kits & reagents segment is expected to be the largest during the forecast period. Standardized methods and reagents are provided by these kits, guaranteeing uniformity and repeatability in experimental processes. This lessens variation across experiments and amongst researchers. These kits work better because they are tailored for particular kinds of samples or sequencing platforms. They frequently have parts designed specifically for difficult sample kinds, enhancing DNA yield and purity.
The shotgun sequencing segment is expected to have the highest CAGR during the forecast period. Without requiring prior knowledge of the species present in the sample, shotgun sequencing is impartial. Since it captures all genetic information, new and unexpected species can be found. It helps to produce hypotheses for more focused research. Researchers might concentrate on particular genes or pathways of interest for in-depth studies by identifying a community's genetic potential.
North America is projected to hold the largest market share during the forecast period. Understanding the wide variety of organisms present is made easier by the extensive analysis of genetic diversity provided by metagenomics in these habitats. The area is leading the way in technical advancements. Technological developments in sequencing and computational techniques facilitate metagenomic research by enabling deeper examination and comprehension of intricate microbial populations.
Asia Pacific is projected to hold the highest CAGR over the forecast period. Researching soil health, discovering useful microbes for agriculture, and addressing environmental issues like pollution in rivers and seas in nations such as China, India, and Japan are all made easier by the use of metagenomics. Metagenomics plays a crucial role in comprehending the microbial communities found in highly populated metropolitan regions, facilitating disease surveillance, and examining the variety of the human microbiome.
Some of the key players in Metagenomics market include Agilent Technologies, BGI Group, Bio-Rad Laboratories, Eurofins Scientific, F. Hoffmann-La Roche Ltd., Illumina, Inc., IntegraGen, Merck KGaA, Novogene Co., Ltd., Oxford Nanopore Technologies, PerkinElmer, Inc., Promega Corporation, Qiagen, Takara Bio, Inc., Thermo Fisher Scientific, Inc. and Trivitron Healthcare Pvt. Ltd.
In September 2022, Illumina, Inc. (US) launched the NovaSeq X series production-scale sequencers, which are capable of generating more than 20,000 whole genomes per year (which is 2.5 times the throughput of prior sequencers from Illumina).
In September 2021, Thermo Fisher Scientific, Inc. (US) and AstraZeneca(UK) co-developed an NGS-based companion diagnostic. The collaboration was focused on commercializing NGS-based diagnostics in Russia.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.